%0 Journal Article
%T A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole
%A Zaida Garcia-Casado
%A Angel Guerrero-Zotano
%A Antonio Llombart-Cussac
%A Ana Calatrava
%A Antonio Fernandez-Serra
%A Amparo Ruiz-Simon
%A Joaquin Gavila
%A Miguel A Climent
%A Sergio Almenar
%A Jose Cervera-Deval
%A Josefina Campos
%A Carlos Albaladejo
%A Antonio Llombart-Bosch
%A Vicente Guillem
%A Jose A Lopez-Guerrero
%J BMC Cancer
%D 2010
%I BioMed Central
%R 10.1186/1471-2407-10-36
%X We analyzed 95 consecutive postmenopausal women with stage II-III ER/PgR [+] BC treated with neoadjuvant letrozole. Response to treatment was measured by radiology at 4th month by World Health Organization (WHO) criteria. Three polymorphisms of CYP19A1, one in exon 7 (rs700519) and two in the 3'-UTR region (rs10046 and rs4646) were evaluated on DNA obtained from peripheral blood.Thirty-five women (36.8%) achieved a radiological response to letrozole. The histopathological and immunohistochemical parameters, including hormonal receptor status, were not associated with the response to letrozole. Only the genetic variants (AC/AA) of the rs4646 polymorphism were associated with poor response to letrozole (p = 0.03). Eighteen patients (18.9%) reported a progression of the disease. Those patients carrying the genetic variants (AC/AA) of rs4646 presented a lower progression-free survival than the patients homozygous for the reference variant (p = 0.0686). This effect was especially significant in the group of elderly patients not operated after letrozole induction (p = 0.009).Our study reveals that the rs4646 polymorphism identifies a subgroup of stage II-III ER/PgR [+] BC patients with poor response to neoadjuvant letrozole and poor prognosis. Testing for the rs4646 polymorphism could be a useful tool in order to orientate the treatment in elderly BC patients.After cessation of ovarian activity at postmenopause, the aromatase [cytochrome P450 19 (CYP19); OMIM:107910] from bones, adipose tissue and muscle, becomes the key enzyme in estradiol and estrone biosynthesis through the aromatization of testosterone and androstenedione respectively [1]. Aromatase is encoded by CYP19A1 which maps at chromosome 15q21.1 and has a complex structure with a region that contains 10 tissue-specific non-coding upstream exons with separate promoters that regulate transcription in different cells and tissues [2]. Elevated levels of aromatase expression have been observed in breast tumors rela
%U http://www.biomedcentral.com/1471-2407/10/36